Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Van Akkooi, A. C. J. Hauschild, A. Long, G. V. Mandalà, M. Kicinski, M. Govaerts, A. S. Klauck, I. Ouali, M. Lorigan, Paul C Eggermont, A. M.
Van Akkooi, A. C. J.
Hauschild, A.
Long, G. V.
Mandalà, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Lorigan, Paul C
Eggermont, A. M.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Van Akkooi ACJ, Hauschild A, Long GV, Mandalà M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005520.